Ivan Koutsopatriy estrogen receptor

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 8: Line 8:
== Structural highlights ==
== Structural highlights ==
-
ER is a modular protein composed of a ligand binding domain, a DNA binding domain and a transactivation domain. ER is a DNA-binding transcription factor. <scene name='71/714947/Er_bound_to_dna_dnadomain/1'> ER bound to DNA with one DNA binding helix and the transactivation domain highlighted yellow </scene> The DNA binding domain can be clearly observed in this scene; the highlighted yellow helix in close proximety to the DNA is part of the DNA binding domain. The blue beta sheet close to the yellow DNA binding alpha helix is also part of the DNA binding domain. The transactivation domain is attached at the end of the yellow DNA binding domain, also forming an alpha helix colored in yellow. The transactivation domain activates RNA polymerase when the receptor binds to DNA. The ligand binding domain may be observed here with the following scene. <scene name='71/714947/Agonist_ferutinine_bound_er/2'> Agonist_ferutinine_bound_er</scene> The ligand ferutinine is bound by surrounding blue colored alpha helices. Unbound ER normally exists loosly around the nucleus; this is subject to change depending on a multitude of factors including cell type, progress through cell cycle and reception of cellular signals. When estrogen enters the cell and binds ER, ER trans-locates and undergoes a conformation shift.<ref> Beato, M., Chavez, S., and Truss, M. (1996). Transcriptional regulation by steroid hormones. Steroids 61: 240–251. </ref> Ligand bound estrogen receptor associates more tightly with the nucleus.
+
ER is a modular protein composed of a ligand binding domain, a DNA binding domain and a transactivation domain. ER is a DNA-binding transcription factor. <scene name='71/714947/Er_bound_to_dna_dnadomain/1'> ER bound to DNA with one DNA binding helix and the transactivation domain highlighted yellow </scene> The DNA binding domain can be clearly observed in this scene; the highlighted yellow helix in close proximety to the DNA is part of the DNA binding domain. The blue beta sheet close to the yellow DNA binding alpha helix is also part of the DNA binding domain. The transactivation domain is attached at the end of the yellow DNA binding domain, also forming an alpha helix colored in yellow. The transactivation domain activates RNA polymerase when the receptor binds to DNA. The ligand binding domain may be observed here with the following scene. <scene name='71/714947/Agonist_ferutinine_bound_er/2'> Agonist_ferutinine_bound_er</scene> The ligand ferutinine is bound by the ligand binding domain, composed of te surrounding blue colored alpha helices . Unbound ER normally exists loosly around the nucleus; this is subject to change depending on a multitude of factors including cell type, progress through cell cycle and reception of cellular signals. When estrogen enters the cell and binds ER, ER trans-locates and undergoes a conformation shift.<ref> Beato, M., Chavez, S., and Truss, M. (1996). Transcriptional regulation by steroid hormones. Steroids 61: 240–251. </ref> Ligand bound estrogen receptor associates more tightly with the nucleus.
Line 15: Line 15:
Ferutinine also causes ER to form a tight loop allowing stimulation of normal growth.
Ferutinine also causes ER to form a tight loop allowing stimulation of normal growth.
-
<scene name='71/714947/Partial_agonist_genistein_er/3'>Partial_Agonist_genistein_bound_Er</scene>
 
-
The conformation of ER bound to genistein has a loop which is not as tight as those found on ER with a complete agonist ligand.
 
-
<scene name='71/714947/Antagonist_tamoxifen_bound_er/5'>Antagonist_tamoxifen_bound_er</scene>
+
 
-
Tamoxifen is a drug created to bind ER and inhibit the transcription factor activity of ER. Tamoxifen is larger than the normal hormone ER binds (estradiol); for this reason the activation loop is pushed into an inactive conformation. This blocks ER from giving the signal to grow.
+
==DNA Protein Interaction and ER Regulation==
==DNA Protein Interaction and ER Regulation==
-
ER is functional as a ligand-dependent transcription factor. <ref> Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG (25 May 2001)."Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.". J Biol Chem. 276 (21): 18375–83. </ref> ER responds to both agonist and antagonist ligands and can associate with the nuclear matrix. Differences in the structure of the receptor is observed depending on what ligand ER has bound. Through comparisons of ER bound to agonist and antagonist ligands some structural components may be highlighted. <scene name='71/714947/Agonist_estradiol_bound_er/2'>Agonist_estradiol_bound_er</scene> The specific conformation of this tight loop creates part of the activation signal that will stimulate normal growth, as estradiol is a normal ligand for ER and allows for binding in the major groove of DNA.The location of the receptor bound and unbound to ligand varies amongst different cell types. In general, an antagonist ligand will cause partial accumulation in the cytoplasm of a cell. The agonist ligand causes the translocation to the nucleus described above.
+
ER is functional as a ligand-dependent transcription factor. <ref> Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG (25 May 2001)."Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.". J Biol Chem. 276 (21): 18375–83. </ref> ER responds to both agonist and antagonist ligands and can associate with the nuclear matrix. Differences in the structure of the receptor are observed depending on what ligand ER has bound. Through comparisons of ER bound to agonist and antagonist ligands some structural components may be highlighted. <scene name='71/714947/Agonist_estradiol_bound_er/2'>Agonist_estradiol_bound_er</scene> The specific conformation of this tight loop creates part of the activation signal that will stimulate normal growth, as estradiol is a normal ligand for ER and allows for binding in the major groove of DNA. If the ligand is an antagonist the transcription factor function of estrogen receptor becomes hindered. <scene name='71/714947/Partial_agonist_genistein_er/3'>Partial_Agonist_genistein_bound_Er</scene> The conformation of ER bound to the partial agonist genistein has a loop which is not as tight as those found on ER with a complete agonist ligand. This is noticeable in the size difference of the pure agonist vs partial agonist scenes.
 +
 
 +
 
 +
<scene name='71/714947/Antagonist_tamoxifen_bound_er/5'>Antagonist_tamoxifen_bound_er</scene>
 +
Tamoxifen is a drug created to bind ER and inhibit the transcription factor activity of ER. Tamoxifen is larger than the normal hormone ER binds (estradiol); for this reason added with the conformation estrogen receptor takes on, the activation loop is pushed into an inactive conformation. This blocks ER from giving the signal to grow. Antagonists are generally larger and cause estrogen receptors to be too hindered sterically to be able to bind to the major groove of DNA, inhibiting the receptor. The antagonist bound estrogen receptor is noticeably larger than the agonist bound version.
 +
 
 +
The location of the receptor bound and unbound to ligand varies amongst different cell types. In general, an antagonist ligand will cause partial accumulation in the cytoplasm of a cell. The agonist ligand causes the translocation to the nucleus described above.
A group bound GFP to ER and studied the location of GFP-ER upon binding of agonists and antagonist ligands. <ref> Htun H, Holth LT, Walker D, Davie JR, Hager GL (1 February 1999). "Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor". Mol Biol Cell 10 (2): 471–86. </ref> GFP-ER activates the reporter gene in a dose-dependent manner and shows additional activation in the presence of agonist ligand 17-bestradiol. ICI 182780, a pure antagonist for ER, completely inhibited GFP-ER activation of the reporter gene.
A group bound GFP to ER and studied the location of GFP-ER upon binding of agonists and antagonist ligands. <ref> Htun H, Holth LT, Walker D, Davie JR, Hager GL (1 February 1999). "Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor". Mol Biol Cell 10 (2): 471–86. </ref> GFP-ER activates the reporter gene in a dose-dependent manner and shows additional activation in the presence of agonist ligand 17-bestradiol. ICI 182780, a pure antagonist for ER, completely inhibited GFP-ER activation of the reporter gene.
The group found that in the absence of ligand, the unoccupied ER is loosely associated with the nucleus.
The group found that in the absence of ligand, the unoccupied ER is loosely associated with the nucleus.

Revision as of 01:32, 28 October 2015

PDB ID 1qku

Drag the structure with the mouse to rotate

References

  1. Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
  2. Beato, M., Chavez, S., and Truss, M. (1996). Transcriptional regulation by steroid hormones. Steroids 61: 240–251.
  3. Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, Lisanti MP, Katzenellenbogen BS, Kato S, Hopp T, Fuqua SA, Lopez GN, Kushner PJ, Pestell RG (25 May 2001)."Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity.". J Biol Chem. 276 (21): 18375–83.
  4. Htun H, Holth LT, Walker D, Davie JR, Hager GL (1 February 1999). "Direct visualization of the human estrogen receptor alpha reveals a role for ligand in the nuclear distribution of the receptor". Mol Biol Cell 10 (2): 471–86.

Proteopedia Page Contributors and Editors (what is this?)

Ivan Koutsopatriy, Michal Harel

Personal tools